NCT06230523

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 263 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits.

Conditions

• Obesity
• Overweight and Obesity

Interventions

Type	Name	Description
DRUG	LY3841136	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2024-02-05
• Primary completion: 2025-05-30
• Completion: 2025-08-14
• First posted: 2024-01-30
• Last updated: 2025-08-28

Locations

46 sites across 2 countries: United States, Argentina

Regulatory

• FDA-regulated drug study